Myriad Genetics saw the highest growth of 2.99% in patent filings in June and 2.99% in grants in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.24% and grants by 0.49%. GlobalData’s DataBook provides a comprehensive analysis of Myriad Genetics‘s patent filings and grants. Buy the databook here.
Myriad Genetics has been focused on protecting inventions in United States(US) with nine publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 100% filings and 80% grants. The United States(US), Canada(CA), and European Patent Office(EPO) patent Office are among the top ten patent offices where Myriad Genetics is filings its patents. Among the top granted patent authorities, Myriad Genetics has 80% of its grants in United States(US) and 20% in Canada(CA).
Patents related to genomics and machine learning lead Myriad Genetics's portfolio
Myriad Genetics has the highest number of patents in genomics followed by, machine learning and rare diseases. For genomics, nearly 38% of patents were filed and 30% of patents were granted in Q2 2024.
Healthcare it related patents lead Myriad Genetics portfolio followed by autonomous driving, and laboratory information management systems
Myriad Genetics has highest number of patents in healthcare it followed by autonomous driving, laboratory information management systems, lung cancer, and prostate cancer.
For comprehensive analysis of Myriad Genetics's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.